Floatz logo

Tigozertinib

Neoplasms, Nerve Tissue

Blueprint Medicines CorporationSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Neoplasms, Nerve Tissue cohort.

Asset / SponsorPhaseRating
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Pembrolizumab
Hoffmann-La Roche
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
Microbubble
NaviFUS Corporation
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Hoffmann-La Roche
Phase 3B

View all 13 →

Same molecule, other indications

Tigozertinib is also rated in:

chemotherapy-induced toxicityDormant
CC
Indicative ·
43 / 100
View asset →
respiratory tract neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →